May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 20, 2025

Five Major Advances in Radiotherapy for Anal and Rectal Cancer Presented at ESTRO 2025

Rectal cancer is one of the most common cancers in Europe, with over 125,000 people diagnosed annually. Treatment traditionally involves surgery to remove the tumor—a major operation that can permanen...

The ASCO Post

May 19, 2025

Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose che...

The ASCO Post

May 13, 2025

GLP-1s May Protect Against Obesity-Related Cancer

First-generation GLP-1 receptor agonists provide comparable protection against obesity-related cancers as bariatric surgery.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 02, 2025

Early-onset Colorectal Cancer Linked to Bacterial Toxin

Childhood exposure to colibactin increases risk of developing CRC before the age of 50.

The Pathologist

May 02, 2024

New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer

The Case Western Reserve University School of Medicine received a 5-year $1.84 million grant to investigate the role of the LRG1 protein in colorectal cancer growth and develop a novel treatment option for patients with metastatic colorectal cancer.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant